Clinical evidence for medical-grade Manuka honey in wound healing, the role of MGO, and where to draw the line between food-grade and medical use.
Medical-grade Manuka honey dressings have the strongest applied evidence base — clinically established for chronic wounds, biofilm-laden ulcers, and antibiotic-resistant infections including MRSA. Food-grade Manuka honey is not a wound dressing and should not be used to self-treat beyond minor superficial scrapes.
Wound care is the part of the Manuka honey story where the gap between mechanism and clinical evidence is narrowest. It is the application that hospitals, district nurses, and tissue viability specialists actually use, with regulated products, established protocols, and a substantial clinical literature behind it. Most of what is true about Manuka honey as a serious therapeutic agent is true here — and that is also why it is the easiest area to mislead people about, by collapsing food-grade and medical-grade into a single category.
The clinical interest concentrates on chronic and complex wounds — venous leg ulcers, diabetic foot ulcers, pressure injuries, surgical wounds with delayed healing, burns, and wounds colonised by antibiotic-resistant organisms. These are wounds where conventional management is challenged by biofilm formation, resistant bacteria, exudate management, and the broader physiology of impaired healing. Manuka honey dressings have been evaluated, and in places routinely used, in exactly those situations.
This page is about the evidence and the principles. It is not a self-treatment guide. The combination of "buy a pot of honey and apply to a wound" is not the use case the clinical literature supports.
Several mechanisms act in parallel in a wound bed.
The first is osmotic action. Honey's very high sugar concentration draws fluid through the wound, which assists in autolytic debridement — the body's own enzymatic removal of necrotic tissue — and reduces local oedema. This effect is shared with sugar-based dressings generally, but it operates alongside the other mechanisms below in a way ordinary sugar does not.
The second is low pH. Honey is mildly acidic (pH around 3.2–4.5), and when applied to a wound it lowers the local environment in a way many wound pathogens tolerate poorly. Lower pH also has favourable effects on oxygen unloading from haemoglobin and on the activity of some enzymes involved in healing.
The third is non-peroxide antibacterial activity attributed mainly to methylglyoxal (MGO). Unlike the peroxide-based activity of ordinary honey, this activity is stable to the conditions of a wound — dilution by exudate, body temperature, and the action of catalase in tissue and serum. Laboratory and clinical work has reported activity against a broad range of wound pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and biofilm-embedded organisms that are notoriously difficult to clear.
The fourth is biofilm disruption. Biofilms — structured communities of bacteria embedded in a self-produced matrix — are a major reason chronic wounds resist healing, and they protect the bacteria within them from antibiotics. Manuka honey at therapeutic concentrations has demonstrated activity against biofilms in laboratory and clinical work, and this is one of the more clinically distinctive arguments for its use in chronic wound care.
The fifth is moist wound healing. Modern wound care is built on the principle that a moist wound bed heals faster and more cleanly than a dry one; honey's viscosity and osmotic profile fit that paradigm well, and Manuka honey dressings produce a moist wound environment without the maceration risks of more aqueous alternatives.
Multiple randomised trials and systematic reviews have evaluated medical-grade Manuka honey dressings in chronic wounds. The signal across this literature is consistent: in chronic venous leg ulcers, diabetic foot ulcers, and biofilm-colonised wounds, Manuka honey dressings perform at least as well as comparator dressings on key outcomes — wound bioburden, time to healing, exudate management — and in some studies outperform them, particularly in wounds with complex bacterial colonisation. The evidence base is not uniformly large, and not all individual trials are positive on every endpoint, but the directional weight is supportive.
The randomised controlled trial summarised on this site is one of the more rigorous applied studies: across three New Zealand clinical sites, UMF 24+ (MGO 1,122+) honey dressings on MRSA-colonised chronic venous leg ulcers showed sustained bactericidal activity over 14 days and no detected resistance-associated mutations on whole-genome sequencing of paired isolates. That methodology — paired clinical isolates, whole-genome sequencing, multi-site recruitment — is closer to what a clinical pharmacology question requires than the in-vitro work that dominates the broader literature.
What the evidence does not show is that food-grade Manuka honey, applied at home, replicates the clinical results of medical-grade dressings. The trials use sterilised, regulated products under clinical care; the conclusions apply to that use. Extrapolating to "Manuka honey heals wounds" without those qualifiers is going further than the evidence does.
For a structured comparison of Manuka grading systems and what each one tells you, the UMF and MGO grading primer walks through the assays, thresholds, and certifications.
For minor, clean, superficial scrapes in healthy people, ordinary first-aid practice — wash with clean water, dry, cover with a clean dressing — is the standard. A small amount of food-grade Manuka honey applied under a dressing on a clean superficial graze is a long-standing tradition; the clinical evidence base for this use is informal rather than rigorous, but it is broadly reasonable for trivial injuries.
For anything beyond that — chronic wounds, ulcers, diabetic skin breaks, infected wounds, surgical wounds with delayed healing, burns beyond superficial sunburn, deep or penetrating injuries, animal or human bites — the appropriate path is clinical: assessment by a clinician, and use of regulated medical-grade Manuka honey dressings if and where they are clinically indicated. Medical-grade dressings are filtered, sterilised, and produced under medical-device standards; they are not the same product as a retail jar, even a premium one. The decision about whether and which Manuka honey product to use belongs with the treating clinician.
If a wound is showing signs of infection — spreading redness, swelling, heat, pus, fever, or red streaking — that is a reason to seek medical care promptly, not to escalate to a higher grade of honey. Manuka honey is one of the most effective parts of the Manuka story when used appropriately; "appropriately" in this context means "in a clinical pathway with the right product", not "from the pantry".
Honey of any kind — including Manuka honey — must not be given to infants under 12 months old, due to the risk of infant botulism. People with bee, pollen, or honey allergies should avoid Manuka honey, including topically.
Wounds are not a self-treatment category. Diabetic foot ulcers, venous leg ulcers, pressure injuries, surgical wound complications, deep or penetrating injuries, animal or human bites, burns beyond superficial sunburn, and any wound showing signs of infection — spreading redness, swelling, heat, pus, fever, or red streaking — require medical assessment. Use of honey on these wounds should be in the context of a clinical care plan with appropriate sterile, regulated medical-grade products, not retail food-grade honey from the pantry.
Food-grade Manuka honey, including premium UMF-graded jars, is not a sterile medical device. It is not the same product as a CE-marked or therapeutic-goods–approved Manuka wound dressing, which is filtered, sterilised, and produced under medical-device standards. People with diabetes or circulatory conditions should be particularly cautious about self-treating any skin break and should involve their healthcare team early.